Last updated: 2026-10-14 23:14:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Tyra Biosciences, Inc. (TYRA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $18.69, with a market capitalization of $1.35B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.35 to $40.65. This page covers its latest market performance, valuation, price trends and company information.
$1.35B | |
$18.44 | |
$40.65 | |
$4.93 | |
$18.56 | |
324.67K | |
855.20K | |
-- | |
$40.65 | |
$13.35 | |
-- | |
-- |
Tyra Biosciences, Inc. (TYRA) is trading at $18.70 in after-hours trading as of 2026-10-14 19:58:00, up 0.75% ($0.14) from the regular-session close of $18.56.
After-hours trading shows how investors are pricing TYRA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Tyra Biosciences, Inc. (TYRA) moved from $20.93 to $18.69, representing a decline of 10.71% ($2.24).
The stock traded between $18.13 and $21.03 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 585.88 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 19.6%
TYRA is currently trading at $18.69, placing it 19.6% of the way from its 52-week low of $13.35 to its 52-week high of $40.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 87 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tyra Biosciences, Inc. (TYRA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.